Dumontet C, Biron P, Bouffet E, Blay J Y, Meckenstock R, Chauvin F, Philip I, Clavel M, Brunat-Mentigny M, Philip T
Centre Léon Bérard, Lyon, France.
Bone Marrow Transplant. 1992 Nov;10(5):405-8.
Twenty-two patients with locally advanced or metastatic soft tissue sarcomas received high dose chemotherapy with autologous bone marrow graft. Eleven patients receiving melphalan also received fractionated total body irradiation. Six patients (four in CR and two in PR) were intensified after first line therapy. Thirteen patients were grafted after chemosensitive relapse: seven in second CR, one in third CR, one in first PR, three in second PR and one in fourth PR. Three patients with primary refractory disease were intensified. The overall response rate in 66% in nine evaluable patients. The overall median survival and disease-free survival were 19 and 15 months, respectively. The actuarial survival rates at 2 and 5 years were 40% and 32% respectively. There was one treatment-related death due to infection. We conclude that high dose chemotherapy is feasible and provides reasonable response rates in patients with advanced soft tissue sarcomas.
22例局部晚期或转移性软组织肉瘤患者接受了高剂量化疗及自体骨髓移植。11例接受美法仑治疗的患者还接受了分次全身照射。6例患者（4例完全缓解，2例部分缓解）在一线治疗后进行了强化治疗。13例患者在化疗敏感复发后进行了移植：7例第二次完全缓解，1例第三次完全缓解，1例第一次部分缓解，3例第二次部分缓解，1例第四次部分缓解。3例原发性难治性疾病患者进行了强化治疗。9例可评估患者的总缓解率为66%。总中位生存期和无病生存期分别为19个月和15个月。2年和5年的精算生存率分别为40%和32%。有1例因感染导致的治疗相关死亡。我们得出结论，高剂量化疗是可行的，并且在晚期软组织肉瘤患者中提供了合理的缓解率。
